‘Grand slam’ pill doubles survival rate for third-deadliest cancer: study

Nypost · 🇺🇸 public United States · Jun 02, 2026 · 688 words · By McKenzie Beard

Patient Survival Rates Medical Innovation Pharmaceutical Efficacy

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Patient Survival Rates

‘Grand slam’ pill doubles survival rate for third-deadliest cancer: study See more of our coverage in your search results.

Claims checked 15

Techniques found 2

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center80%

Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

‘Grand slam’ pill doubles survival rate for third-deadliest cancer: study See more of our coverage in your search results.

Why it matters

Add The New York Post on GoogleThere’s new hope for one of the world’s deadliest cancers.

Common ground

Groundbreaking clinical trial results show that an experimental new drug could double survival time for pancreatic cancer patients.

Perspective signals

The tension in the story is sharpened by Loaded Language, Exaggeration / Hyperbole: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Patient Survival Rates story?
What evidence would most clearly confirm or weaken the claim that Pancreatic cancer is among the hardest cancers to diagnose and treat, with just 13% of patients surviving five years after diagnosis?
How does this story connect Patient Survival Rates with Medical Innovation over the next few days?

open_in_new Read the original article: https://nypost.com/2026/06/02/health/new-pill-doubles-survival-rate-for-third-de…

psychologyPropaganda Techniques Detected

eFinder identified 2 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 90% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Exaggeration / Hyperbole 80% confidence

Overstating facts or claims to create a stronger emotional response.

Why it matters: Recognizing exaggeration / hyperbole helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 15 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 7

schedule Pending 5

info Single Source 2

help Insufficient Evidence 1

check_circle

Claim 1: “Pancreatic cancer is among the hardest cancers to diagnose and treat, with just 13% of patients surviving five years after diagnosis.”

CORROBORATED

Multiple independent news sources (CNBC, NY Post, Denver7) all explicitly state the five-year survival rate for pancreatic cancer is 13%.

menu_book

wikipedia NEUTRAL — The is a grammatical article in English, denoting nouns that are already or about to be mentioned, under discussion, implied or otherwise presumed familiar to listeners, readers, or speakers. It is th…
https://en.wikipedia.org/wiki/The

menu_book

wikipedia NEUTRAL — The is the definite article in English. The, or THE, may also refer to:
https://en.wikipedia.org/wiki/The_(disambiguation)

menu_book

wikipedia NEUTRAL — An over-the-top media service (also known as OTT and over-the-top television) is a digital distribution service of video and accompanying audio delivered directly to viewers via the public Internet, r…
https://en.wikipedia.org/wiki/Over-the-top_media_service

+ 5 more evidence sources

schedule

Claim 2: “The agency is also allowing what’s called “expanded access” to the treatment for patients who meet certain criteria.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

info

Claim 3: “Severe side effects were reported by 43.6% of daraxonrasib patients, compared to 57.5% on chemotherapy.”

SINGLE SOURCE

While web results discuss side effects and mention chemotherapy being 'more commonly' associated with certain events, the specific percentages (43.6% and 57.5%) are not explicitly corroborated across multiple independent sources in the provided evidence.

travel_explore

web search NEUTRAL — May 31, 2026 · The most common serious treatment-related adverse events that led to hospitalization were gastrointestinal events in both the daraxonrasib group ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

travel_explore

web search NEUTRAL — May 8, 2026 · Rash was the most frequent severe side effect, occurring in 14% of patients, followed by stomatitis or mouth sores & inflammation, which ...
https://www.linkedin.com/posts/ming-hei-tai-pharmd-bcop-7334…

travel_explore

web search NEUTRAL — May 31, 2026 · The most common serious treatment-related side effects with daraxonrasib included rash and stomatitis, while chemotherapy was more commonly ...
https://news.cancerconnect.com/daraxonrasib-in-pancreatic-ca…

schedule

Claim 4: “In, December, doctors told him he had three to four months to live.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 5: “In the trial, 500 patients whose pancreatic cancer had spread to distant organs — and who had stopped responding to chemotherapy — were split into two groups getting either chemotherapy or a once-daily oral dose of daraxonrasib.”

CORROBORATED

Multiple web sources confirm a trial of 500 patients with metastatic pancreatic cancer who had previously failed chemotherapy were treated with daraxonrasib.

menu_book

wikipedia NEUTRAL — There are many $500 banknotes, bills or coins, including: Nicaraguan five hundred-cordoba note One of the withdrawn Canadian banknotes One of the banknotes of the Hong Kong dollar One of the banknote…
https://en.wikipedia.org/wiki/$500

menu_book

wikipedia NEUTRAL — 500 may refer to: 500 (number) 500 BC AD 500
https://en.wikipedia.org/wiki/500

menu_book

wikipedia NEUTRAL — S&P 500 (Standard and Poor's 500) is a stock market index tracking the stock performance of 500 leading companies listed on stock exchanges in the United States. It is one of the most commonly followe…
https://en.wikipedia.org/wiki/S&P_500

+ 3 more evidence sources

schedule

Claim 6: “In 2026 alone, the American Cancer Society estimates that 67,530 new cases will be diagnosed, and more than 52,740 people across the country will die from the disease.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 7: “former GOP Sen. Ben Sasse revealed he was taking it for Stage 4 pancreatic cancer, telling the New York Times in April that the volume of tumors in his torso had dropped by 76%.”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

schedule

Claim 8: “The Food and Drug Administration previously announced it plans to fast-track its review of daraxonrasib”

PENDING

This claim was extracted as a checkable statement from the article. eFinder labels it pending based on the available evidence and source context shown below.

check_circle

Claim 9: “Patients taking the daily pill lived, on average, about six months longer than those who received chemotherapy alone”

CORROBORATED

Multiple sources confirm the median survival increase. Specifically, CNBC reports an increase of 6.5 months (13.2 vs 6.7), which aligns with 'about six months longer'.

travel_explore

web search NEUTRAL — Jun 16, 2026 ... In a groundbreaking study, the experimental drug daraxonrasib extended the lives of patients with metastatic pancreatic cancer to a median of ...
https://www.facebook.com/cancer.gov/posts/in-case-you-missed…

travel_explore

web search NEUTRAL — May 31, 2026 ... The median progression-free survival in the RAS G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

travel_explore

web search NEUTRAL — Jun 9, 2026 ... Roughly half were randomly assigned to receive daraxonrasib, and the other half received chemotherapy of the investigator's choice. · Median ...
https://www.mskcc.org/news/how-daraxonrasib-could-improve-pa…

check_circle

Claim 10: “The most common severe side effects were rash, affecting 14% of patients, and mouth sores, affecting 12%.”

CORROBORATED

Multiple sources confirm rash and stomatitis/mouth sores as the most frequent severe side effects, with one source explicitly citing 14% for rash and another mentioning mouth sores.

travel_explore

web search NEUTRAL — Jun 1, 2026 ... In the Phase 1/2 study, most patients had some treatment-related adverse event. Common side effects included rash, diarrhea, nausea, stomatitis ...
https://passionhealthphysicians.com/daraxonrasib-pancreatic-…

travel_explore

web search NEUTRAL — May 31, 2026 ... 57.5%). The most commonly reported treatment-related adverse events in the daraxonrasib group were rash (in 85.5% of the patients), diarrhea (in ...
https://www.nejm.org/doi/full/10.1056/NEJMoa2605555

travel_explore

web search NEUTRAL — May 8, 2026 ... This phase 1/2 study, just published in the NEJM, gives some more insights into the side effect profile of daraxonrasib .
https://www.linkedin.com/posts/ming-hei-tai-pharmd-bcop-7334…

check_circle

Claim 11: “Researchers found that patients on daraxonrasib lived a median of 13.2 months, compared to 6.7 months for those on chemotherapy”

CORROBORATED

The specific figures (13.2 months vs 6.7 months) are consistently reported across CNBC, Wikipedia, and multiple medical news reports.

menu_book

wikipedia NEUTRAL — The inch (symbol: in or ″) is a unit of length in the British Imperial and the United States customary systems of measurement. It is equal to ⁠1/36⁠ yard or ⁠1/12⁠ of a foot. Derived from the Roman un…
https://en.wikipedia.org/wiki/Inch

menu_book

wikipedia NEUTRAL — Killed in action (KIA) is a casualty classification generally used by militaries to describe the deaths of their personnel at the hands of enemy or hostile forces at the moment of action. The United S…
https://en.wikipedia.org/wiki/Killed_in_action

menu_book

wikipedia NEUTRAL — IN, In or in may refer to:
https://en.wikipedia.org/wiki/In

+ 4 more evidence sources

help

Claim 12: “Just 1.2% of daraxonrasib users stopped treatment due to side effects, compared to 11.2% on chemotherapy.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results to confirm or deny the specific discontinuation rates of 1.2% and 11.2%.

info

Claim 13: “That number plummets to 3% when the disease is caught at an advanced stage”

SINGLE SOURCE

The American Cancer Society (authoritative reference) explicitly lists the 5-year relative survival rate for 'Distant' (advanced) stage pancreatic cancer as 3%.

travel_explore

web search NEUTRAL — Jan 13, 2026 ... SEER* Stage. 5-year Relative Survival Rate ; Localized. 44% ; Regional. 17% ; Distant. 3% ; All SEER stages combined. 13% ...
https://www.cancer.org/cancer/types/pancreatic-cancer/detect…

travel_explore

web search NEUTRAL — In contrast, the 5-year survival rate for localized disease rose from 24% to 46%, while the stage distribution only slightly increased from 11% to 14% during ...
https://pmc.ncbi.nlm.nih.gov/articles/PMC12175802/

travel_explore

web search NEUTRAL — Feb 26, 2026 ... Pancreatic cancer remains one of the toughest cancers to treat, and today the five-year relative survival rate is still low at about 13%. That ...
https://www.cityofhope.org/hope-matters-blog/why-pancreatic-…

check_circle

Claim 14: “The drug, manufactured by Revolution Medicines, works by blocking a mutant protein that drives tumor growth in more than 90% of pancreatic cancer patients.”

CORROBORATED

Wikipedia confirms daraxonrasib is a RAS inhibitor by Revolution Medicines. Multiple web sources confirm it targets a mutant protein driving growth in >90% of pancreatic cancer patients.

menu_book

wikipedia NEUTRAL — The following scientific events occurred, or are scheduled to occur in 2026.
https://en.wikipedia.org/wiki/2026_in_science

menu_book

wikipedia NEUTRAL — Daraxonrasib (RMC-6236) is a RAS inhibitor drug. It is undergoing testing by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcin…
https://en.wikipedia.org/wiki/Daraxonrasib

travel_explore

web search NEUTRAL — Apr 13, 2026 ... Pancreatic cancer is the most RAS-addicted of all major cancers, with more than 90% of patients harboring tumors driven by mutations in RAS ...
https://ir.revmed.com/news-releases/news-release-details/dar…

+ 2 more evidence sources

check_circle

Claim 15: “the drug cut the risk of death by 60%.”

CORROBORATED

The 60% reduction in risk of death (hazard ratio 0.40) is explicitly cited by CNBC, The Straits Times, and other reports.

menu_book

wikipedia NEUTRAL — Zoldonrasib, also known as RMC-9805, is an investigational drug that selectively targets the G12D mutation in KRAS dependent cancers. Zoldonrasib functions as molecular glue that forms a non-covalent …
https://en.wikipedia.org/wiki/Zoldonrasib

menu_book

wikipedia NEUTRAL — Benjamin Eric Sasse ( SASS; born February 22, 1972) is an American politician and academic administrator. He represented Nebraska in the United States Senate from 2015 to 2023, resigning to become th…
https://en.wikipedia.org/wiki/Ben_Sasse

+ 4 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.